MP53-03 REAL-WORLD RESPONSE TO FIRST LINE PLATINUM-BASED CHEMOTHERAPY IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA

You have accessJournal of UrologyBladder Cancer: Invasive V (MP53)1 May 2024MP53-03 REAL-WORLD RESPONSE TO FIRST LINE PLATINUM-BASED CHEMOTHERAPY IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA Sandra Kim, Josh Ma, Bernie Eigl, Nimira Alimohamed, Girish Kulkarni, Peter Chung, Jeffrey Graham, Rodney Breau, Michael Ong, Eric Levesque, Naveen Basappa, Ricardo Rendon, Jean Castilloux, Eric Winquist, Robert Siemens, Jean-Baptiste Lattouf, Som Mukherjee, Daniel Yokom, Wassim Kassouf, and Peter Black Sandra KimSandra Kim , Josh MaJosh Ma , Bernie EiglBernie Eigl , Nimira AlimohamedNimira Alimohamed , Girish KulkarniGirish Kulkarni , Peter ChungPeter Chung , Jeffrey GrahamJeffrey Graham , Rodney BreauRodney Breau , Michael OngMichael Ong , Eric LevesqueEric Levesque , Naveen BasappaNaveen Basappa , Ricardo RendonRicardo Rendon , Jean CastillouxJean Castilloux , Eric WinquistEric Winquist , Robert SiemensRobert Siemens , Jean-Baptiste LattoufJean-Baptiste Lattouf , Som MukherjeeSom Mukherjee , Daniel YokomDaniel Yokom , Wassim KassoufWassim Kassouf , and Peter BlackPeter Black View All Author Informationhttps://doi.org/10.1097/01.JU.0001008784.37684.bd.03AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Contemporary real-world reports of outcomes for patients with locally advanced or metastatic (LA/mUC) urothelial carcinoma are limited. Especially with the advent of switch maintenance immunotherapy and the availability of established second and third line treatment options, it has become imperative to better characterize real-world patient outcomes after first line chemotherapy. The objective of this study was to determine real world practice patterns and outcomes after first line platinum-based chemotherapy in a large multi-centre cohort of LA/mUC. METHODS: The Canadian Bladder Cancer Information System (CBCIS) is a national prospectively maintained database across 15 academic institutions in Canada. Patients who received systemic therapy for locally advanced (cT4b or cN1-3) or metastatic urothelial carcinoma of the bladder were included between January 2015 and April 2023. Patients were included if they had to have at least one follow-up imaging after the initiation of systemic therapy. Treatment parameters and response rates were assessed. RESULTS: A total of 501 patients received first line systemic therapy for LA/mUC of whom 370 (73.9%) received platinum-based chemotherapy. Of those receiving platinum-based chemotherapy, 190 (51.4%) patients received cisplatin/gemcitabine and 172 (46.5%) patients received carboplatin/gemcitabine. Treatment was completed in 97 (26%) of 370 patients and discontinued in 140 (37.8%). Fourty-seven (33.8%) patients stopped treatment due to progression and 68 (48.9%) due to an adverse event. Of the 370 patients undergoing platinum-based chemotherapy with documented response status, complete response was observed in 4 (1.1%) patients, partial response or stable disease in 121 (32.9%) patients, and progression in 99 (26.9%) patients. Second line systemic therapy was administered to 245 (48.9%) patients who received first line systemic therapy. Switch maintenance with avelumab was used in 59 (15.9%) patients after platinum based chemotherapy. The median follow-up from the time of diagnosis was 10.4 months. CONCLUSIONS: The real-world response rates after first line platinum-based chemotherapy in this study are lower than previously reported. This study highlights the need for further research to better evaluate the true real-world effects of treatment in locally advanced and metastatic urothelial carcinoma. Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e863 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Sandra Kim More articles by this author Josh Ma More articles by this author Bernie Eigl More articles by this author Nimira Alimohamed More articles by this author Girish Kulkarni More articles by this author Peter Chung More articles by this author Jeffrey Graham More articles by this author Rodney Breau More articles by this author Michael Ong More articles by this author Eric Levesque More articles by this author Naveen Basappa More articles by this author Ricardo Rendon More articles by this author Jean Castilloux More articles by this author Eric Winquist More articles by this author Robert Siemens More articles by this author Jean-Baptiste Lattouf More articles by this author Som Mukherjee More articles by this author Daniel Yokom More articles by this author Wassim Kassouf More articles by this author Peter Black More articles by this author Expand All Advertisement PDF downloadLoading ...